Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 5/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.37 |
| ▸ | TYMP | P19971 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465208 | 0.85 | PARP1 (0.56) | PARP1ADORA3 | |
| SCHEMBL31624240 | 0.72 | PLAT (0.48) | PLATGRM2PARP1KDM5BRAD51 | |
| SCHEMBL23998523 | 0.72 | PARP1 (0.58) | PARP1KDM5BADORA3 | |
| SCHEMBL28990869 | 0.72 | PLAT (0.47) | PLATGRM2PARP1KDM5BRAD51 | |
| SCHEMBL14373987 | 0.70 | KDM4E (0.47) | PARP1 | |
| SCHEMBL24693475 | 0.70 | HAVCR2 (0.33) | TYMP | |
| SCHEMBL18788145 | 0.69 | GRM2 (0.46) | GRM2RAD51 | |
| SCHEMBL9423003 | 0.67 | GSK3B (0.44) | PLATPARP1KDM5BADORA3RAD51 | |
| SCHEMBL17730629 | 0.67 | PLAT (1.00) | PLAT | |
| Hydrochloric Acid SCHEMBL19611709 | 0.66 | PLAT (0.98) | PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000497-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BY) | 2018-06-19 | — | — | US | disclosed |
| US-20170121337-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121337-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | PLAT 4535/4885GRM2 2093/4885PARP1 863/4885 |
| US-10000497-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | PI4KB, PI4KA, PI4K2B | PLAT 4535/4885GRM2 2093/4885PARP1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.